Apixaban Resumption After Dental Procedure
For most dental procedures, resume apixaban 5 mg twice daily 24 hours after the procedure once adequate hemostasis is established 1, 2.
Risk-Stratified Approach
The timing of apixaban resumption depends on the bleeding risk of the dental procedure:
Low Bleeding Risk Dental Procedures
- Simple extractions, root canals, routine cleanings
- Resume full-dose apixaban (5 mg twice daily) 24 hours post-procedure 1
- The FDA label supports restarting "as soon as adequate hemostasis has been established" 2
- Canadian guidelines suggest 48 hours for low-risk procedures (24-48 hour range) 3
High Bleeding Risk Dental Procedures
- Multiple extractions, surgical extractions, periodontal surgery
- Resume full-dose apixaban (5 mg twice daily) 48-72 hours post-procedure 1
- For patients at high thromboembolic risk, consider reduced-dose apixaban 2.5 mg twice daily starting at 24 hours, then increase to full dose at 48-72 hours 1
Key Clinical Considerations
Hemostasis must be confirmed before any resumption. The rapid onset of apixaban (peak effect 1-3 hours) means premature resumption carries significant bleeding risk 1. Ensure the surgical site shows stable clot formation and no active oozing.
No bridging anticoagulation is needed. Unlike warfarin, apixaban's rapid onset eliminates the need for heparin bridging during the interruption period 2.
Most minor dental procedures can be performed without stopping apixaban. Simple cleanings, single-tooth extractions, and root canals can often proceed with continued anticoagulation using local hemostatic measures (tranexamic acid mouthwash, sutures, hemostatic agents) 1, 4. However, recent observational data suggests that brief perioperative discontinuation of DOACs may reduce bleeding risk compared to continuation 5.
Practical Algorithm
- Assess procedure bleeding risk (low vs. high)
- Assess patient thromboembolic risk (CHADS₂ score, mechanical valve, recent stroke)
- For low-risk procedures: Resume at 24 hours if hemostasis adequate
- For high-risk procedures: Resume at 48-72 hours if hemostasis adequate
- For high thromboembolic risk patients undergoing high-risk procedures: Consider reduced dose (2.5 mg BID) at 24 hours, then full dose at 48-72 hours
Common Pitfalls
Resuming too early: The 2018 EHRA guidelines emphasize waiting "1 day after hemostasis is established" (meaning 48 hours for low-risk, 72 hours for high-risk procedures) 6. This is more conservative than older guidelines but reflects growing concern about post-procedural bleeding with DOACs.
Forgetting dose adjustments: Patients on reduced-dose apixaban (2.5 mg BID) for other indications should resume their usual dose, not automatically increase to 5 mg 2.
Inadequate local hemostasis: Relying solely on timing without confirming hemostasis. Always verify stable clot formation before restarting.
The evidence base for DOAC management in dental procedures remains limited, with most guidelines extrapolating from surgical data 1, 3, 6. The 24-hour resumption for low-risk procedures represents a balance between thrombotic and bleeding risks, supported by both FDA labeling and expert consensus 2.